Shares of eBay Inc. (EBAY) are up by 4% to $55.64 in early trade Thursday, after the company announced a standstill agreement with activist investor Carl Icahn that will give investors a greater say in its PayPal payments segment after it is spun off. The e-commerce company also said it will explore a sale or IPO of its enterprise business.
In other eBay news this morning, the name was upgraded to ‘Equal-weight’ from ‘Underweight’ at Morgan Stanley (MS). The upgrade comes after the company said it plans to reduce its work force by 7% this quarter.
On valuation measures, eBay Inc. shares have a PEG and forward P/E ratio of 1.51 and 15.27, respectively. Price/Sales for the same period is 3.79 while EPS is ($0.10). Currently there are 14 analysts that rate EBAY a ‘Buy’, 22 rate it a ‘Hold’. 2 analysts rate it a ‘Sell’. EBAY has a median Wall Street price target of $58.00 with a high target of $69.00.
In the past 52 weeks, shares of San Jose, Calif.-based company have traded between a low of $46.34 and a high of $59.70. Shares are down 1.42% year-over-year, and 4.88% year-to-date.
FXCM Inc. (FXCM) – The stock is up over 11% to $2.65 in early trading Thursday after jumping 30% Wednesday. The move comes on a big volume too with the issue currently trading more than 33.6 million shares, well ahead of its three month daily average of 3.5 million shares.
FXCM Inc. is a New York-based online foreign exchange (FX) trading service provider. Its stock has a median consensus analyst price target of $4.50, and a 52-week trading range of $1.28 to $17.97. The stock is down more than 85% year-over-year and has lost roughly 86% year-to-date.
FXCM Inc. has a current market cap of $122 million.
Shares of Minerva Neurosciences, Inc. (NERV) are higher by 15% to $5.02 on heavy volume in early trading on Thursday, after the company reported positive Phase 1 data with MIN-202- Selective Orexin-2 Antagonist for treatment of sleep disorders including primary and Comorbid Insomnia.
Minerva Neurosciences, Inc. is currently valued at $91.51M. The name has a median Wall Street price target of $11.00 per share. Approximately 1.1 million shares have already changed hands, compared to the stock’s average daily volume of 136.424K.
In the past 52 weeks, shares of Cambridge, Massachusetts-based biopharmaceutical company have traded between a low of $4.08 and a high of $10.00 with the 50-day MA and 200-day MA located at $5.13 and $5.66 levels, respectively. Additionally, shares have a Relative Strength Index (RSI) and MACD indicator of 51.08 and -0.79, respectively.
NERV currently prints a one year loss of 18%, and a year-to-date loss of around 17%.
BlackBerry Limited (BBRY) is higher by approximately 8% this morning, after the Financial Post reported that Samsung Electronics is actively pursuing the acquisition of all or part of the company, despite statements from both companies this week denying that such a takeover plan may be in the works.
BlackBerry Limited gained $0.76 to $10.69 in morning trading today. Approximately 14M shares have already changed hands, compared to the stock’s average daily volume of 13.72M shares.
On valuation-measures, shares of BlackBerry have a P/E to growth ratio of -1.22. T-12 profit margin is (20.68%). EPS registers at ($1.43). The company has a market cap of $5.58B and a median Wall Street price target of $10.00 with a high target of $17.00.
On trading-measure, BBRY has a beta of 0.05 and a short float of 24.60%. In the past 52 weeks, shares of Waterloo, Canada-based smartphone maker have traded between a low of $7.01 and a high of $12.63 with its 50-day MA and 200-day MA located at $10.45 and $10.25 levels, respectively.
BBRY currently prints a one year loss of 1.16%.
Advaxis, Inc. (ADXS) is trading at unusually high volume Wednesday with 3.1 million shares changing hands. It is currently at 5x its average daily volume and trading down 10% at $7.51. Not seeing any news or rumors to account for the move.
Advaxis, Inc., is a Princeton, New Jersey-based clinical stage biotechnology company that focuses on the discovery and commercialization of Lm-LLO cancer immunotherapies in the United States. Its stock has a 52-week trading range of $2.46 to $13.74.
Shares in the $143 million market cap company are up 41% year-over-year.